Eyal Weinstein

InspireMD Ltd. is a medical device company, which engages in the development and commercialization of platform technology for the treatment of vascular and coronary disease. It offers MicroNet stent, a device designed to trap and seal thrombus and plaque against the vessel wall, preventing embolization. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Owlytics Healthcare operates personalized physiology-tracking health detection platform. The company was founded by Gill Zaphrir and Yaron Recher in 2015 and is headquartered in Tel Aviv, Israel.

Arsenal Medical Inc. develops therapeutic products based on BioActive Composites platform. Its biomaterials-based systems provide targeted local and systemic therapies to treat chronic diseases and conditions. The firm product offers tailored dosing of drugs, mechanical and biochemical compatibility with tissues and complete bioabsorption. The company was founded by George M. Whitesides, Carmichael S. Roberts Jr. and Robert S. Langer Jr. in 2005 and is headquartered in Watertown, MA.

Creare, Inc. provides engineering research, development and consulting services. The firm specializes in fluid dynamics and heat transfer, cryogenics, robotics, data systems, advanced materials, control systems, and aerospace and biomedical engineering. Its projects range from analysis and computational modeling to prototype fabrication and testing. The company was founded in 1961 and is headquartered in Hanover, NH.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland.

Qart Medical Ltd. is a medical, a clinical-stage medtech company, addressing the global infertility epidemic. The company was founded by Alon Shalev and Natan T. Shaked and is headquartered in Israel.

CardiacSense Ltd. is a digital health company based in Caesarea, Israel. The Israeli company has developed a medical watch that integrates proprietary patent-protected sensors and software algorithms to provide continuous measurement of parameters such as core temperature, respiratory rate, blood pressure, oxygen saturation, and heart rate at CE and FDA-mandated accuracies. This provides an alternative to costly and complex invasive devices, addressing the increasing demand for remote patient monitoring and tele-health. The private company was founded in 2009 by Eldad Shemesh and Liat Shemesh, with Eldad Shemesh serving as the CEO since incorporation.

ClearCut Medical Ltd. develops proprietary technology and tools for removal of cancer. Its product ClearSightTM MRI System, focuses on breast cancer lumpectomy for intraoperative margin assessment of surgically removed lumps. The firms applications include breast cancer biopsies, margin assessment of skin cancer, prostate cancer, colorectal cancer and lung cancer tissue microstructure. The company was founded by Eyal Kolka and Erez Golan in 2010 and is headquartered in Rehovot, Israel.

PulmOne Advanced Medical Devices Ltd. develops devices designed to allow lung function testing. It manufactures and distributes the MiniBox, an office based solution providing complete lung function testing in a portable device. The company was founded by Avi Lazar in 2006 and is headquartered in Raanana, Israel.

EndoSpan Ltd. develops novel endovascular system for endovascular aortic aneurysm repair. The firm is opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The company was founded by Rafi Benary and Alon Shalev in 2009 and is headquartered in Herzlia, Israel.

Part of Medtronic Plc, Mazor Robotics LLC is a company that specializes in the Mazor X Stealth Edition robotic guidance platform. The company is based in Orlando, FL. The platform is equipped with advanced software, robotic technologies, navigation, and instrumentation to support predictable surgical procedures. Christopher Prentice has been the CEO of the company since 2014.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Pharmacentra LLC provides marketing and communications programs for the pharmaceutical and insurance industries. The private company is based in Norcross, GA. The CEO of the company is Dan Berman.

Rebiotix, Inc. develops and commercializes medical therapies. It offers human microbiome, clostridium difficile, inflammatory bowel disease or ulcerative colitis, hepatic encephalopathy, multi-drug resistant organism, and microbiota restoration therapies. The company was founded by Lee A. Jones, Michael Berman, and Erwin A. Kelen in 2011 and is headquartered in Roseville, MN.

AgNovos Healthcare LLC is a medical technology company that develops new products using regenerative medicine to address bone disease. The company is based in Rockville, MD, where they have their corporate headquarters, manufacturing, research & development, and corporate support services. The company's first product, the Ossure® Local Osteo-Enhancement Procedure Kit, is CE-marked to form new bone in the pelvis and extremities. AgNovos Healthcare was founded in 2012 by James Howe and Tanner Howe, with Tanner Howe serving as the CEO since then.

Caliber Imaging & Diagnostics, Inc. operates as a medical technologies company. It designs, develops, and markets imaging solutions for use in applications such as dermatology, neurological sciences, developmental biology, pathology, and translational research. The firm offers VIVANET and VIVASCAN. The company was founded in 1991 and is headquartered in Andover, MA.

Covidien Unlimited Co. engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings. It operates through Medical Devices and U.S. Medical Supplies segments. The Medical Devices segment involves in the distribution of surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. The U.S. Medical Supplies segment includes marketing of nursing care, medical surgical, SharpSafety brand, and original equipment manufacturer (OEM) products. The company was founded in 1967 and is headquartered in Dublin, Ireland.

CBSET, Inc. is a not-for-profit biomedical research institute located in Lexington, MA. The non-profit company's mission is to advance biomedical research through innovative, high-quality preclinical services to achieve the scientific, regulatory, and commercial goals of its sponsors. CBSET combines top-tier research with operational expertise by providing in vivo studies, in vitro studies, computational and 3D modeling, and complex histopathology services. The company's 40,000-foot, GLP-compliant, OLAW-assured, AAALAC-accredited facility includes vivaria, procedure rooms, catheterization/imaging labs, surgical and necropsy suites, histopathology, SEM, and a range of other technologies.

The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA.

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in 2007 and is headquartered in Redwood City, CA.

Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA.

Fidelity Management & Research Co. (FMR) is a SEC-registered investment advisor headquartered in Boston, Massachusetts. The firm was founded in 1946 and is a subsidiary of FMR LLC, also known as Fidelity Investments. FMR provides investment supervisory services, which include sub-advisory services, to Fidelity's family of mutual funds and exchange-traded funds, qualified tuition programs, privately offered unregistered investment funds, separately managed account clients, and various other institutional accounts.